References
Boronat B, Jeffrey M, Gelfand M et al (2013) Encephalitis and antibodies to DPPX, a subunit of Kv42 potassium channels. Ann Neurol 73(1):120–128
Tobin W, Lennon V, Komorowki L et al (2014) DPPX potassium channel antibody. Neurology 83(20):1797–1803
Hara M, Arino H, Sabater L et al (2017) DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 88(14):1340–1348
Peipgras J, Holtje M, Klaus M et al (2015) Anti-DPPX encephalitis. Pathogenic effects of antibodies on gut and brain neurons. Neurology 85(10):890–897
Currie S, Hadjivassiliou M, Craven I et al (2013) Magnetic resonance spectroscopy of the brain. Postgrad Med J 89(1048):94–106
Shibaski H, Hallett M (2005) Electrophysiological studies of myoclonus. Muscle Nerve 31(2):157–174
Cassim F, Houdayer E (2006) Neurophysiology of myoclonus. Clin Neurophysiol 36(5–6):281–291
Croccu G, Aminoff MJ, Curio G et al (2008) Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 119(8):1705–1719
Hadjivassiliou M, Graus F, Honnorat J et al (2017) Diagnostic criteria for primary autoimmune cerebellar ataxia-guidelines from an international task force on immune-mediated cerebellar ataxias. Cerebellum. https://doi.org/10.1007/s12311-020-01132-8
Acknowledgements
The authors would like to thank Dr Patrick Waters for his work in setting up the DPPX assay. This is a summary of independent research carried out at the NIHR Sheffield Biomedical Research Centre (Translational Neuroscience). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflicts of interest to disclose.
Ethical standards
This article summarizes observational case series of 3 patients with DPPX-ARA being managed at the Sheffield Ataxia Centre (SAC), Sheffield UK. The South Yorkshire Research Ethics Committee has confirmed that no ethical approval is indicated given that immunosuppression is a recognized treatment for DPPX-ARA and that all investigations/interventions were clinically indicated and did not form part of a research study.
Data access, responsibility and analysis
The corresponding author had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Rights and permissions
About this article
Cite this article
Pattrick, M., Sarrigiannis, P.G., Kruger, S. et al. Brain hyper-excitability in DPPX ataxia. J Neurol 267, 3096–3099 (2020). https://doi.org/10.1007/s00415-020-10182-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-10182-1